Table 4.
Multivariate Cox proportional hazards ratios for association between HER2 measurements by HERmark, selected clinicopathological variables and overall survival
| Overall survival | ||
|---|---|---|
| HR | P value | |
| Model A | ||
| HERmark positive vs. negative* | 3.1 | 0.034 |
| Grade 3 vs. 1 or 2 | 2.0 | 0.26 |
| Stage III or IV vs. I or II | 0.93 | 0.89 |
| Node positive vs. negative | 1.7 | 0.38 |
| Hormone receptor positive vs. negative | 0.43 | 0.071 |
| Model B | ||
| H2T high vs. low# | 3.9 | 0.0061 |
| Grade 3 vs. 1 or 2 | 1.7 | 0.30 |
| Stage III or IV vs. I or II | 0.91 | 0.84 |
| Node positive vs. negative | 1.9 | 0.26 |
| Hormone receptor positive vs. negative | 0.54 | 0.15 |
*HERmark status based on HERmark analytical cutoffs in Model A: HERmark positive - H2T >17.8 relative fluorescence (RF)/mm2; HERmark negative - H2T <10.5 RF/mm2. #HER2 levels based on HERmark clinical cutoff in Model B: H2T high - H2T >13.8 RF/mm2; H2T low- H2T ≤13.8 RF/mm2. HER2, human epidermal growth factor receptor 2; H2T, quantitative total HER2 expression by HERmark; HR, hazard ratio.